A South & Central America Biologics Market Forecast to 2031 - Regional Analysis - by Product (Monoclonal Antibodies, Vaccine, Recombinant Hormones/Proteins, Cell and Gene Therapy, and Others)

The South & Central America biologics market was valued at US$ 16,517.2 million in 2023 and is expected to reach US$ 54,534.7 million by 2031; it is estimated to register a CAGR of 16.1% from 2023 to 2031.

Gene and Cell Therapy Advancements in Biologics Regions Fuel South & Central America Biologics Market

Gene and cell therapies are among the most promising and rapidly growing segments in the biologics market. These therapies have the potential to cure or significantly alleviate diseases by addressing their root causes at the genetic or cellular level rather than just managing symptoms. Gene therapies involve introducing or modifying genetic material in a patient’s cells to treat or prevent disease. Significant progress has been made in treating genetic disorders such as sickle cell anemia, muscular dystrophy, and certain inherited forms of blindness. The development of gene-editing technologies, particularly CRISPR, has further improved the precision and effectiveness of these therapies, making them viable options for conditions that were previously untreatable. Cell therapies, including stem cell and CAR-T (Chimeric Antigen Receptor T-cell) therapies, provide innovative treatments for various conditions, including certain cancers, autoimmune diseases, and tissue regeneration. CAR-T therapies, in particular, have transformed the treatment of blood cancers by utilizing the patient’s immune cells to attack cancer cells directly. The complexity and specialization of gene and cell therapies present high-value opportunities for biologics manufacturers. Despite challenges related to production, cost, and regulatory approval, the potential for groundbreaking, life-saving treatments makes this an expanding and lucrative market segment.

South & Central America Biologics Market Overview

The biologics market in South & Central America is segmented into Brazil, Argentina, and the Rest of South & Central America. The rising prevalence of genetic disease, growing demand for personalized medicines and biologics, and surging number of product launches with technological advancements are expected to contribute to the growth of the market in this region. As per a study titled Medical genetics workforce in Brazil: practitioners, services, and disease distribution, published in 2021, ~53,746 live births were diagnosed with rare genetic diseases in 2019–2020, while 498 cases were with a hereditary cancer syndrome. The study titled The Brazilian Rare Genomes Project, published in May 2022, states that 13.2 million individuals were affected by rare diseases in Brazil. The rising prevalence of genetic disease, along with chronic illness, is the primary factor driving the growth of the biologics market in Brazil. The country has a robust domestic pharmaceutical production capacity, which enables its trade activities and contributes notably to its GDP. As per the US Department of Commerce, domestic companies, such as Hypermarcas and EMS Sigma Pharma, account for ~80% of the total pharmaceutical companies in Brazil. Such a well-positioned pharmaceutical and biopharmaceutical industry supports the growth of the biologics market in Brazil. Bevacizumab, cetuximab, and panitumumab are the three main monoclonal antibodies approved for treating metastatic colorectal cancer (mCRC) in the country.

South & Central America Biologics Market Revenue and Forecast to 2031 (US$ Million)

South & Central America Biologics Market Segmentation

The South & Central America biologics market is categorized into product, application, source, manufacturing, and country.

Based on product, the South & Central America biologics market is segmented into monoclonal antibodies, vaccine, recombinant hormones/proteins, cell and gene therapy, and others. The monoclonal antibodies segment held the largest market share in 2023.

In terms of application, the South & Central America biologics market is categorized into cancer, infectious diseases, autoimmune diseases, and others. The cancer segment held the largest market share in 2023.

By source, the South & Central America biologics market is bifurcated into mammalian and microbial. The mammalian segment held a larger market share in 2023.

Based on manufacturing, the South & Central America biologics market is bifurcated into outsourced and in-house. The outsourced segment held a larger market share in 2023.

In terms of country, the South & Central America biologics market is segmented into Brazil, Argentina, and the Rest of South & Central America. Brazil dominated the South & Central America biologics market share in 2023.

AbbVie Inc; Pfizer Inc; Samsung Biologics Co Ltd; ADMA Biologics, Inc.; Wuxi Biologics Inc; Catalent Inc; AGC Biologics AS; AstraZeneca Plc; Amgen Inc; Nitto Avecia; and Quality Assistance s.a. are some of the leading companies operating in the South & Central America biologics market.

Reasons to buy

Save and reduce time carrying out entry-level research by identifying the growth, size, leading players, and segments in the South & Central America biologics market.
Highlights key business priorities to assist companies to realign their business strategies.
The key findings and recommendations highlight crucial progressive industry trends in the South & Central America biologics market, thereby allowing players across the value chain to develop effective long-term strategies.
Develop/modify business expansion plans by using substantial growth offering developed and emerging markets.
Scrutinize in-depth South & Central America market trends and outlook coupled with the factors driving the South & Central America biologics market, as well as those hindering it.
Enhance the decision-making process by understanding the strategies that underpin commercial interest with respect to client products, segmentation, pricing, and distribution.